{
    "clinical_study": {
        "@rank": "112764", 
        "arm_group": [
            {
                "arm_group_label": "High Risk of CTE", 
                "arm_group_type": "Experimental", 
                "description": "Subjects at high risk of developing CTE (former National Football League players) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "Control subjects (former non-contact athletes) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic\n      encephalopathy (CTE) and examine the relationship between clinical presentation and tau\n      deposition."
        }, 
        "brief_title": "18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Traumatic Encephalopathy", 
        "condition_browse": {
            "mesh_term": [
                "Brain Damage, Chronic", 
                "Delirium", 
                "Encephalitis", 
                "Hepatic Encephalopathy", 
                "Neurotoxicity Syndromes", 
                "Brain Injuries", 
                "Dementia", 
                "Brain Injury, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subjects consented and currently enrolled in the Diagnosing and Evaluating\n             Traumatic Encephalopathy Using Clinical Tests (DETECT) study protocol\n\n          -  Can tolerate up to two PET imaging sessions\n\n          -  Have the ability to provide informed consent for study procedures\n\n        Exclusion Criteria:\n\n          -  Claustrophobia\n\n          -  Current clinically significant cardiovascular disease or clinically significant\n             abnormalities on screening ECG\n\n          -  History of risk factors for Torsades de Pointes or are taking drugs known to cause\n             QT-prolongation\n\n          -  Current clinically significant infectious disease, endocrine or metabolic disease,\n             pulmonary, renal or hepatic impairment, or cancer that the investigator believes\n             would affect study participation or scan results\n\n          -  Have had a non-study related radiopharmaceutical imaging or treatment within 7 days\n             prior to study PET imaging sessions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "69 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079766", 
            "org_study_id": "18F-AV-1451-A07"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "High Risk of CTE", 
                    "Control"
                ], 
                "intervention_name": "florbetapir F 18", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Amyvid", 
                    "18F-AV-45"
                ]
            }, 
            {
                "arm_group_label": [
                    "High Risk of CTE", 
                    "Control"
                ], 
                "intervention_name": "18F-AV-1451", 
                "intervention_type": "Drug", 
                "other_name": "T807"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02118"
                }, 
                "name": "Research Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy", 
        "overall_contact": {
            "email": "clinicaloperations@avidrp.com", 
            "last_name": "Avid Clinical Operations", 
            "phone": "215-298-0700"
        }, 
        "overall_official": {
            "affiliation": "Avid Radiopharmaceuticals, Inc.", 
            "last_name": "Chief Medical Officer", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "18F-AV-1451 uptake and florbetapir F 18 standard uptake value ratio (SUVR) will be compared in subjects with a high risk of CTE and controls.", 
                "measure": "CTE Biomarker Analysis", 
                "safety_issue": "No", 
                "time_frame": "Up to 100 minutes post injection"
            }, 
            {
                "description": "The relationship among 18F-AV-1451 uptake, florbetapir SUVR, and measurements including neuropsychological assessment battery (NAB) List and Story Learning tests, Trail Making Test - Parts A and B, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale - Revised (WAIS-R), Animal Fluency, NAB Naming Test, NAB Map Reading Test and Mini-Mental State Examination (MMSE).", 
                "measure": "Relationship Between Clinical Presentation and Tau Deposition", 
                "safety_issue": "No", 
                "time_frame": "Up to 100 minutes post injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079766"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Avid Radiopharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Avid Radiopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}